Evidence map›Paper›PMID 32683667›Full record

Observational studyAdvances in therapy2020

Evaluation of Nurses' and Patients' Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR

Brigitte Delemer, Thierry Nguyen-Tan-Hon, Romain Coriat, Denis Smith, Frank Schillo, Isabelle Raingeard, Iradj Sobhani, Pierre-Luc Etienne, Benedicte Decoudier, Ségolène Bisot-Locard and 3 more

Abstract readComparative StudyMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Brigitte DelemerEndocrinology, Diabetology and Nutrition Unit, University Hospital of Reims, Reims, France.ORCID http://orcid.org/0000-0002-4320-2601
Thierry Nguyen-Tan-HonMedical Oncology Unit, University Hospital of Besançon, Besançon, France.ORCID http://orcid.org/0000-0002-4014-5779
Romain CoriatGastroenterology Unit, Cochin Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University of Paris, Paris, France.ORCID http://orcid.org/0000-0003-4420-8340
Denis SmithDigestive Oncology Unit, Haut-Levêque Hospital, University Hospital of Bordeaux, Pessac, France.ORCID http://orcid.org/0000-0003-3155-6709
Frank SchilloDiabetology Outpatient Unit, University Hospital of Besançon, Besançon, France.ORCID http://orcid.org/0000-0003-3219-5845
Isabelle RaingeardEndocrinology, Diabetology and Nutrition Unit, University of Montpellier, Montpellier, France.
Iradj SobhaniGastroenterology Unit, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.ORCID http://orcid.org/0000-0003-1031-0080
Pierre-Luc EtienneMedical Oncology, CARIO-HPCA Center, Plérin, France.ORCID http://orcid.org/0000-0002-7549-9892
Benedicte DecoudierEndocrinology, Diabetology and Nutrition Unit, University Hospital of Reims, Reims, France.ORCID http://orcid.org/0000-0002-5000-681X
Ségolène Bisot-LocardMedical Oncology, Novartis, Rueil Malmaison, France.ORCID http://orcid.org/0000-0001-5619-9758
Alexandre SantosMedical Oncology, Novartis, Rueil Malmaison, France.ORCID http://orcid.org/0000-0003-1519-3231
Gerald RaverotEndocrine Department, Louis Pradel Hospital, Hospices Civils of Lyon, Lyon, France.ORCID http://orcid.org/0000-0002-9517-338X
Guillaume CadiotHepatogastroenterology and Digestive Oncology Unit, University Hospital of Reims, Reims, France. gcadiot@chu-reims.fr.ORCID http://orcid.org/0000-0002-2726-8715

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe first long-acting release (LAR) formulation of octreotide was marketed in France in the late 1990s. An injectable formulation of Sandostatin LAR

methodsWe conducted an observational, cross-sectional and multicenter study in France whose main outcome was to compare nurses' satisfaction with the preparation and administration of both previous and new formulations of octreotide LAR. Secondary outcomes included assessment of patient satisfaction (quality of life and pain felt during the injection) and product tolerance. Data were collected at two time points (one for the first formulation group and one for the second formulation group) through paper questionnaires administered to physicians, patients and nurses including a visual analog scale (VAS) from 0 (unsatisfied) to 10 (very satisfied).

resultsResults showed that overall nurse satisfaction improved from 5.3 (95% CI 4.9-5.8) with the previous formulation to 7.5 (95% CI 7-7.9) with the new formulation (p < 0.0001). Regarding secondary outcomes, the simplicity of the injection increased (84% for the previous formulation and 94% for the new formulation) and the purge problem disappeared (36% for the previous formulation and 4% for the new formulation).

conclusionThe improvement due to the new formulation of Sandostatin LAR

Indexed as

Administration, OralInjectionsAcromegalyAdultAgedAntineoplastic Agents, HormonalCross-Sectional StudiesDelayed-Action PreparationsFemaleFranceHumansMaleMiddle AgedNursing StaffOctreotidePatient SatisfactionAntineoplastic Agents, HormonalDelayed-Action PreparationsOctreotideAcromegalyNeuroendocrine tumorsNursesPatientsQuality of lifeSatisfactionSomatostatin LAR

Identifiers

PMID32683667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.